Ashwani Verma
Stock Analyst at UBS
(2.21)
# 2,686
Out of 4,862 analysts
67
Total ratings
40.43%
Success rate
-0.51%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Neutral | $61 | $69.22 | -11.88% | 1 | Jun 3, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $137 → $152 | $125.01 | +21.59% | 8 | May 6, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $47 → $41 | $33.20 | +23.49% | 5 | May 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $55 → $48 | $33.33 | +44.01% | 2 | Apr 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $25 → $22 | $21.74 | +1.20% | 4 | Apr 28, 2025 | |
| ALKS Alkermes | Maintains: Neutral | $38 → $33 | $30.78 | +7.21% | 4 | Apr 28, 2025 | |
| CHRS Coherus Oncology | Maintains: Neutral | $1.5 → $1.05 | $0.79 | +32.84% | 5 | Apr 24, 2025 | |
| JAZZ Jazz Pharmaceuticals | Upgrades: Buy | $145 → $179 | $110.30 | +62.29% | 6 | Mar 7, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $30 → $27 | $17.71 | +52.46% | 8 | Jan 30, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $30 → $34 | $41.78 | -18.62% | 2 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $14 | $9.34 | +49.89% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $415 → $475 | $286.14 | +66.00% | 4 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $66.36 | +71.79% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $54 | $15.59 | +246.38% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $105 | $106.29 | -1.21% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $35.27 | -20.61% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $76 → $81 | $37.91 | +113.66% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $80.95 | -91.35% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $9.09 | +32.01% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.56 | +2,576.18% | 1 | Oct 11, 2022 |
Incyte
Jun 3, 2025
Maintains: Neutral
Price Target: $61
Current: $69.22
Upside: -11.88%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $137 → $152
Current: $125.01
Upside: +21.59%
Cytokinetics
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $33.20
Upside: +23.49%
Harmony Biosciences Holdings
Apr 28, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $33.33
Upside: +44.01%
ACADIA Pharmaceuticals
Apr 28, 2025
Maintains: Buy
Price Target: $25 → $22
Current: $21.74
Upside: +1.20%
Alkermes
Apr 28, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $30.78
Upside: +7.21%
Coherus Oncology
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $0.79
Upside: +32.84%
Jazz Pharmaceuticals
Mar 7, 2025
Upgrades: Buy
Price Target: $145 → $179
Current: $110.30
Upside: +62.29%
Teva Pharmaceutical Industries
Jan 30, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $17.71
Upside: +52.46%
Exelixis
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $34
Current: $41.78
Upside: -18.62%
Jan 13, 2025
Maintains: Buy
Price Target: $22 → $14
Current: $9.34
Upside: +49.89%
Jan 8, 2025
Maintains: Buy
Price Target: $415 → $475
Current: $286.14
Upside: +66.00%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $66.36
Upside: +71.79%
Aug 13, 2024
Maintains: Buy
Price Target: $55 → $54
Current: $15.59
Upside: +246.38%
Aug 6, 2024
Maintains: Buy
Price Target: $107 → $105
Current: $106.29
Upside: -1.21%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $35.27
Upside: -20.61%
Mar 18, 2024
Maintains: Buy
Price Target: $76 → $81
Current: $37.91
Upside: +113.66%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $80.95
Upside: -91.35%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $9.09
Upside: +32.01%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $0.56
Upside: +2,576.18%